Liam Davenport

Liam Davenport October 28, 2025 TOPLINE: A form of T-cell therapy targeting a highly expressed antigen in uveal melanoma , a

Experts hail the ‘very exciting” discovery that the oft-observed protection against triple-negative breast cancer afforded by breastfeeding may be due to resident T cells left behind in the breast.

The hypoxia-inducible factor-2-α (HIF-2α) inhibitor belzutifan demonstrated clinically meaningful and durable responses in patients with advanced pheochromocytoma and paraganglioma, according to findings from a phase II clinical trial. However, further research will need to confirm its effectiveness and when it should be given to patients relative to other therapies.

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

A clinical trial designed to test an AI-based skin cancer detection app has some surprising results.

Adjuvant therapy improves neither melanoma-specific nor overall survival in patients with stage III disease, conclude Swedish researchers in an updated population-based study.

A retrospective study highlights the potential for encephalitis and other serious neurologic side effects over the course of immune checkpoint inhibitor therapy.

Patients undergoing resection of Merkel cell carcinoma have improved distant metastasis-free survival with adjuvant pembrolizumab — but any benefits for overall survival remain to be seen.

Liam Davenport July 07, 2026 Immune checkpoint inhibitors (ICIs) have been transformative in the treatment of certain cancers, but